ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0034 • ACR Convergence 2024

    Arthritogenic Subdoligranulum (S. Dido 7) Is Increased in Individuals At-Risk for and with Early RA and Decreases over Time During Development of Inflammatory Arthritis

    Lyndsey Cole1, Sucai Liu2, Brendan Allen2, Marie Feser3, Kristen Demoruelle4, Kevin Deane5, Michael Holers3 and Kristine Kuhn6, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 6University of Colorado, Aurora, CO

    Background/Purpose: Subdoligranulum didolesgii, S. dido 7, is present in a subset of individuals who are at-risk for RA (termed ‘ARI’) and who have clinical RA,…
  • Abstract Number: 0051 • ACR Convergence 2024

    Impact of Tight Junction Proteins on Inflammatory Processes and Microbial Imbalance in Rheumatoid Arthritis

    Arkaitz Mucientes1, jose Manuel Lisbona-Montañez2, Patricia Ruiz-Limón3, Sara Manrique-Arija4, Aimara García-Studer4, Fernando Ortiz-Márquez4, Natalia Mena Vázquez5 and Antonio Fernández-Nebro6, 1IBIMA Plataforma BIONAND, Malaga, Andalucia, Spain, 2University of Malaga, Malaga, Andalucia, Spain, 3IBIMA, Instituto de Biomedicina de Málaga, Cordoba, Spain, 4Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 5IBIMA, Málaga, Andalucia, Spain, 6Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain

    Background/Purpose: The etiology of Rheumatoid Arthritis (RA) is not fully understood. Recent studies point to intestinal permeability as an important factor in the establishment and…
  • Abstract Number: 0087 • ACR Convergence 2024

    SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion

    Ethan Jung1, Marie semana1, Ivan Cheng1, Helena Silva1, Sandro Vivona1, Somya Singh1, Michele Bauer1, Mohammed Ali1, Henry Rosas1, Woei Chang1, Deepti Rokkam1, Patrick Lupardus1, Martin Oft1 and Paul-Joseph Aspuria2, 1Synthekine, Menlo Park, 2Sythekine, Menlo Park, CA

    Background/Purpose: CD19 CAR-T therapy has demonstrated efficacy in autoimmune (AI) diseases like systemic lupus erythematosus (SLE) and lupus nephritis (LN), showing its potential beyond oncology.…
  • Abstract Number: 0202 • ACR Convergence 2024

    Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors

    Maria Suarez-Almazor1, Juan Ruiz2, Xiudong Lei1, Hui Zhao1, Suja Rajan3, Heather Lin1 and Sharon Giordano1, 1MD Anderson Cancer Center, Houston, TX, 2MD Anderson, Houston, TX, 3The University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
  • Abstract Number: 0310 • ACR Convergence 2024

    I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study

    Amine Mouamnia, Armentieres Hospital Center, Armentieres, France

    Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
  • Abstract Number: 0449 • ACR Convergence 2024

    Evaluating Premenstrual Dysphoric Disorder in Women with Rheumatoid Arthritis and Healthy Female Subjects

    Ana Cecilia Bardan-Inchaustegui1, Iris Jazmín Colunga Pedraza2, Rosa Icela Arvizu-Rivera2, Gisela Garcia-Arellano3, Griselda Serna-Peña4, Maria F. Elizondo-Benitez5, Aleydis Gonzalez Melendez2, Fernanda Massiel Garcia6 and Dionicio Galarza-Delgado7, 1Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, 5Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 6Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome, is classified as a psychiatric disorder characterized by moderate to severe physical, affective, or…
  • Abstract Number: 0471 • ACR Convergence 2024

    Understanding the Role of the Complement System in Insulin Resistance and Metabolic Syndrome in Patients with Rheumatoid Arthritis

    Jose Viotti-Serra1, Maria Garcia-Gonzalez2, Fuensanta Gomez-Bernal1, Juan Carlos Quevedo-Abeledo3, Miguel Angel Gonzalez-Gay4 and ivan Ferraz-Amaro5, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, 2Hospital Universitario de Canarias, SC Tenerife, Canarias, Spain, 3Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de GC, Canarias, Spain, 4University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, 5Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain

    Background/Purpose: The complement (C) system has been associated with the etiopathogenesis of rheumatoid arthritis (RA). Insulin resistance (IR) and metabolic syndrome are prevalent among RA…
  • Abstract Number: 0488 • ACR Convergence 2024

    Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis

    Pablo Martínez Calabuig1, Elena Grau García2, Samuel Leal Rodriguez2, Ernesto Tovar Sugrañes3, José Ivorra-Cortés4, Carmen Riesco Barcena3, Anderson Huaylla Quispe3, Laura Mas Sánchez5, Pablo Muñoz Martínez6, Daniel Ramos Castro3, Alba Torrat noves7, Iago Alcantara Alvarez8, Belén Villanueva Mañés8, Miguel Simeo Vinaixa8, Andrés Pérez Hurtado3 and Jose A Román-Ivorra9, 1HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, 2HUP La Fe, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Spain, 4Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, 5Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, 6Hospital Universitario y Politècnico La Fe, Sagunto, Spain, 7Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, 8Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 9Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
  • Abstract Number: 0505 • ACR Convergence 2024

    UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi

    George Karpouzas1, Lixia Zhang2, Mark Zielinski2, Brian Cheng2 and Sherry Guardiano3, 1Harbor-UCLA Medical Center, Torrance, CA, 2Scipher Medicine Corporation, Waltham, MA, 3Scipher Medicine Corporation, Keene, NH

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are generally the first class of biologic disease modifying anti-rheumatic drugs (DMARDs) prescribed for rheumatoid arthritis (RA) patients with…
  • Abstract Number: 0522 • ACR Convergence 2024

    Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment

    Soo Min Ahn, Mi-Ra Cho, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo and Seokchan Hong, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…
  • Abstract Number: 0678 • ACR Convergence 2024

    Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually

    Oliver Distler1, Margarida Alves2, Gerrit Toenges3 and Anna-Maria Hoffmann-Vold4, 1Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, 3Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 4Oslo University Hospital, Oslo, Norway

    Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
  • Abstract Number: 0871 • ACR Convergence 2024

    Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”

    Juergen Rech1, Prof. Dr. Andreas Hess2, Koray Tascilar1, Dr. Hannah Schenker3, verena schönau1, Marina Sergeeva2, Jutta Prade2, Silke Kreitz2, Mageshva Sulvakumar2, Laura Konerth2, Sandra Strobelt2, Matthias Englbrecht4, Prof. Dr. Dr. Axel Hueber5, Eugen Feist6, Prof. Dr. Mario Zaiss1, Gerd Burmester7, Frank Behrens8, Dr. Michaela Koehm9, Prof. Dr. Christoph Baerwald10, Dr. Stephanie Finzel11, Dr. Arnd Kleyer12, Prof. Dr. Reinhard Voll11, Dr. Julie Roesch13, Prof. Dr. Arnd Doerfler13, Prof. Dr. Nemanja Damjanov14, Prof. José António P. Da Silva15 and Georg Schett16, 1Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Institute for Experimental Pharmacology FAU Erlangen-Nürnberg, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Department of Internal Medicine 1 - Gastroenterology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 4Freelance Healthcare Data Scientist, Eckental, 5Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, + Rheumatologie, Klinik für Innere Medizin 5, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland, Erlangen, Germany, 6Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 9Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, 10Medizinische Klinik III - Bereich Rheumatologie, Liebigstraße 20, 04103 Leipzig, Leipzig, Germany, 11Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Hugstetterstraße 55, 79106 Freiburg, Freiburg, Germany, 12Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Charité - Universitätsmedizin Berlin Med. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie Berlin, Erlangen, Germany, 13Department of Neuroradiology, Friedrich - Alexander - Universitaet Erlangen - Nuernberg and Universitaetsklinikum Erlangen , Erlangen , Germany, Erlangen, Germany, 14Belgrade University School of Medicine, Institute Institute of Rheumatology, Belgrade, Belgrade, Serbia, 15Head of Department Reumatologia. Hospitais da Universidade (SRHUC), Coimbra, Portugal, 16Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…
  • Abstract Number: 0936 • ACR Convergence 2024

    Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis

    Priyanka Kushwaha1, Catherine Manning2, Tadatoshi Sato3, Yeon-Suk Yang3, Jae-Hyuck Shim4 and Ellen Gravallese5, 1Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, 2Brigham and Women's Hospital, Dedham, MA, 3Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, 4University of Massachusetts, Worcester, MA, 5Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

    Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
  • Abstract Number: 0983 • ACR Convergence 2024

    Life Satisfaction in Adults Living with Arthritis – a Cross-Sectional Analysis of the 2022 National Health Interview Survey

    Aleksander Lenert1, Mary E. Charlton1, Jacob J. Oleson1, Robyn Domsic2 and Polly Ferguson3, 1University of Iowa, Iowa City, IA, 2Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 3University of Iowa Carver College of Medicine, Iowa City, IA

    Background/Purpose: General well-being, an individual’s subjective assessment of their life overall, may be impacted by arthritis. It is unclear if adults with arthritis have lower…
  • Abstract Number: 1041 • ACR Convergence 2024

    A Theory of Change for Patient-Initiated Follow-Up Care in Rheumatoid Arthritis

    Manuel Ester1, Krista White2, Kiran Dhiman2, Saania Zafar2, Alexandra Charlton3, Glen Hazlewood4, Gabrielle L. Zimmermann5, Alison Hoens6, Sarah L. Manske7, Diane Lacaille8, Mark G. Perry9, Megan R.W. Barber10, Aurore Fifi-Mah4, Niki Panich11, Monika Szpunar12, Karen Then13, Kelly Osinski14, Shakeel Subdar15, Hafsah Al-Azem16, Michelle Jung16 and Claire Barber4, 1McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary; O’Brien Institute for Public Health, Cumming School of Medicine, University of Calgary; Arthritis Research Canada, Calgary, AB, Canada, 2McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 3Division of Rheumatology, Cumming School of Medicine, Calgaru, AB, Canada, 4University of Calgary, Calgary, AB, Canada, 5Alberta SPOR SUPPORT Unit – Learning Health System Team, Department of Medicine, University of Alberta; 6. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Edmonton, AB, Canada, 6Arthritis Research Canada; Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, 7McCaig Institute for Bone and Joint Health, Cumming School of Medicine, University of Calgary; Department of Radiology, University of Calgary, Calgary, AB, Canada, 8Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 9Department of Rheumatology, University Hospitals Plymouth; Peninsula Medical School, Plymouth, England, United Kingdom, 10Arthritis Research Canada; Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 11Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 12Arthritis Research Canada, Toronto, ON, Canada, 13Faculty of Nursing, University of Calgary, Calgary, AB, Canada, 14Alberta Health Services, Edmonton, AB, Canada, 15Temerty School of Medicine, University of Toronto, Toronto, ON, Canada, 16Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

    Background/Purpose: Timely, high-quality care is critical to effective rheumatoid arthritis (RA) management. Due to the resource-intensive nature of routine lifelong follow-ups and rheumatologist shortages, RA…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology